CN112020506B - 新生霉素类似物与脯氨酸的共晶体形式 - Google Patents
新生霉素类似物与脯氨酸的共晶体形式 Download PDFInfo
- Publication number
- CN112020506B CN112020506B CN201980011980.6A CN201980011980A CN112020506B CN 112020506 B CN112020506 B CN 112020506B CN 201980011980 A CN201980011980 A CN 201980011980A CN 112020506 B CN112020506 B CN 112020506B
- Authority
- CN
- China
- Prior art keywords
- proline
- crystal
- crystals
- concentration
- starting composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410935084.1A CN118894894A (zh) | 2018-02-07 | 2019-02-01 | 新生霉素类似物与脯氨酸的共晶体形式 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627570P | 2018-02-07 | 2018-02-07 | |
| US62/627,570 | 2018-02-07 | ||
| PCT/US2019/016304 WO2019156907A1 (en) | 2018-02-07 | 2019-02-01 | Co-crystal forms of a novobiocin analog and proline |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410935084.1A Division CN118894894A (zh) | 2018-02-07 | 2019-02-01 | 新生霉素类似物与脯氨酸的共晶体形式 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112020506A CN112020506A (zh) | 2020-12-01 |
| CN112020506B true CN112020506B (zh) | 2024-10-11 |
Family
ID=65444361
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980011980.6A Active CN112020506B (zh) | 2018-02-07 | 2019-02-01 | 新生霉素类似物与脯氨酸的共晶体形式 |
| CN202410935084.1A Pending CN118894894A (zh) | 2018-02-07 | 2019-02-01 | 新生霉素类似物与脯氨酸的共晶体形式 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410935084.1A Pending CN118894894A (zh) | 2018-02-07 | 2019-02-01 | 新生霉素类似物与脯氨酸的共晶体形式 |
Country Status (19)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020016205A2 (pt) | 2018-02-07 | 2020-12-15 | Reata Pharmaceuticals, Inc. | Formas cocristalinas de prolina e de análogo de novobiocina |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| CN115181146B (zh) * | 2021-04-02 | 2024-06-04 | 浙江普洛家园药业有限公司 | 一种新生霉素的提取工艺 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104271587A (zh) * | 2012-02-09 | 2015-01-07 | 堪萨斯大学 | Hsp90C端抑制剂 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013006651A2 (pt) | 2010-09-23 | 2017-07-18 | Nuformix Ltd | composição e cocristal de aprepitante l-prolina |
| TWI542596B (zh) * | 2011-05-09 | 2016-07-21 | 健生藥品公司 | (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體 |
| CN108640910A (zh) * | 2011-11-25 | 2018-10-12 | 诺弗米克斯技术有限公司 | 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体 |
| EP2602249B1 (en) * | 2011-12-06 | 2015-08-12 | F.I.S. Fabbrica Italiana Sintetici S.p.A. | Synthesis of rosuvastatin by means of co-crystals |
| US9556216B2 (en) * | 2012-08-31 | 2017-01-31 | Novartis Ag | 2′-Ethynyl nucleoside derivatives for treatment of viral infections |
| TW201512201A (zh) * | 2013-03-14 | 2015-04-01 | Forum Pharmaceuticals Inc | 化合物的多晶型及鹽類 |
| CA3289739A1 (en) | 2014-06-24 | 2025-11-29 | The University Of Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
| PT3202772T (pt) * | 2014-09-30 | 2020-11-20 | Jiangsu Hengrui Medicine Co | Cristal de um complexo de l-prolina/inibidor do cotransportador de sódio-glicose 2 |
| BR112020016205A2 (pt) | 2018-02-07 | 2020-12-15 | Reata Pharmaceuticals, Inc. | Formas cocristalinas de prolina e de análogo de novobiocina |
-
2019
- 2019-02-01 BR BR112020016205-1A patent/BR112020016205A2/pt unknown
- 2019-02-01 TW TW112106332A patent/TWI868593B/zh active
- 2019-02-01 WO PCT/US2019/016304 patent/WO2019156907A1/en not_active Ceased
- 2019-02-01 KR KR1020207025571A patent/KR102718111B1/ko active Active
- 2019-02-01 MX MX2020008326A patent/MX2020008326A/es unknown
- 2019-02-01 EA EA202091885A patent/EA202091885A1/ru unknown
- 2019-02-01 IL IL315865A patent/IL315865A/en unknown
- 2019-02-01 TW TW108104336A patent/TWI797249B/zh active
- 2019-02-01 TW TW113147071A patent/TWI915111B/zh active
- 2019-02-01 CA CA3090646A patent/CA3090646C/en active Active
- 2019-02-01 PE PE2020001199A patent/PE20211446A1/es unknown
- 2019-02-01 EP EP19705879.5A patent/EP3749675B1/en active Active
- 2019-02-01 CA CA3226385A patent/CA3226385A1/en active Pending
- 2019-02-01 US US16/265,256 patent/US10717755B2/en active Active
- 2019-02-01 IL IL276583A patent/IL276583B2/en unknown
- 2019-02-01 KR KR1020247033920A patent/KR20240155354A/ko not_active Ceased
- 2019-02-01 JP JP2020542665A patent/JP2021512910A/ja not_active Ceased
- 2019-02-01 SG SG11202007530XA patent/SG11202007530XA/en unknown
- 2019-02-01 CN CN201980011980.6A patent/CN112020506B/zh active Active
- 2019-02-01 MY MYPI2020004057A patent/MY209803A/en unknown
- 2019-02-01 AU AU2019217821A patent/AU2019217821B2/en active Active
- 2019-02-01 CN CN202410935084.1A patent/CN118894894A/zh active Pending
- 2019-02-05 AR ARP190100277A patent/AR114245A1/es unknown
-
2020
- 2020-06-05 US US16/894,461 patent/US11401294B2/en active Active
- 2020-08-06 CO CONC2020/0009761A patent/CO2020009761A2/es unknown
- 2020-08-06 MX MX2022012856A patent/MX2022012856A/es unknown
- 2020-08-07 CL CL2020002051A patent/CL2020002051A1/es unknown
-
2022
- 2022-12-05 AU AU2022283638A patent/AU2022283638B2/en active Active
- 2022-12-27 CL CL2022003784A patent/CL2022003784A1/es unknown
-
2023
- 2023-02-13 US US18/168,495 patent/US20240043465A1/en not_active Abandoned
- 2023-10-05 JP JP2023173340A patent/JP2024001167A/ja not_active Withdrawn
-
2024
- 2024-10-25 AU AU2024227646A patent/AU2024227646A1/en active Pending
-
2025
- 2025-10-23 JP JP2025178611A patent/JP2026012851A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104271587A (zh) * | 2012-02-09 | 2015-01-07 | 堪萨斯大学 | Hsp90C端抑制剂 |
Non-Patent Citations (3)
| Title |
|---|
| Development of a pharmaceutical cocrystal with solution crystallization technology: Preparation, characterization, and evaluation of myricetin-proline cocrystals;Mingyu Liu等;European Journal of Pharmaceutics and Biopharmaceutics;第107卷;151-159 * |
| L.Roy等.Pharmaaceutical salts and Co-crystals.RSC,2012,247-279. * |
| The role of cocrystals in pharmaceutical science;Ning Shan等;Drug Discovery Today;第13卷(第9/10期);440-446 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2753603B1 (en) | Polymorphic form of pridopidine hydrochloride | |
| US20240043465A1 (en) | Co-crystal forms of a novobiocin analog and proline | |
| KR20160118204A (ko) | 2-하이드록시-6-((2-(1-이소프로필-1h-피라졸-5-일)피리딘-3-일)메톡시)벤즈알데하이드의 유리 염기의 결정성 다형체 | |
| US20160068530A1 (en) | Solid state forms of vemurafenib and vemurafenib salts | |
| US20260022115A1 (en) | Polymorphic forms of a substituted-quinoxaline-type bridged-piperdine compound | |
| US12473277B2 (en) | Solid forms of a modulator of hemoglobin | |
| HK40119275A (en) | Co-crystal forms of a novobiocin analog and proline | |
| EA049105B1 (ru) | Формы сокристаллов аналога новобиоцина и пролина | |
| RU2838992C2 (ru) | Кристаллические формы ингибитора янус-киназы | |
| EA043335B1 (ru) | Формы сокристаллов аналога новобиоцина и пролина | |
| WO2026018176A1 (en) | 2-(4-chloro-2 methoxyphenyl)-2-((3-methoxy-5-(methylsulfonyl)phenyl)amino)-1-(5-(trifluoro¬methoxy)-1h-indol-3-yl)ethanone and pharmaceutical compositions comprising the same | |
| TW200302830A (en) | Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate | |
| HK1199728B (en) | Polymorphic form of pridopidine hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |